Company
Alexion
Alexion has 35 drugs tracked on RxWires: 3 post-market, 5 in Phase 3, 10 in Phase 2, 3 in Phase 1/2, 13 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Eculizumab | Post-Market | Paroxysmal Nocturnal Hemoglobinuria |
| Oral Corticosteroid Tapering Schedule | Post-Market | Generalized Myasthenia Gravis |
| andexanet alfa | Post-Market | Acute Intracranial Hemorrhage |
| eneboparatide | Phase 3 | Chronic Hypoparathyroidism |
| Ravulizumab | Phase 3 | Amyotrophic Lateral Sclerosis |
| ALXN1840 | Phase 3 | Wilson Disease |
| ALXN2220 | Phase 3 | Transthyretin Amyloid Cardiomyopathy |
| CAEL-101 | Phase 3 | AL Amyloidosis |
| ACH-0137171 | Phase 2 | HCV Infection |
| Tarperprumig | Phase 2 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis |
| ALXN2030 | Phase 2 | Antibody-Mediated Rejection |
| PRT060128 Potassium | Phase 2 | Myocardial Infarction |
| ALXN2420 | Phase 2 | Acromegaly |
| ALXN1830 | Phase 2 | Generalized Myasthenia Gravis |
| Sebelipase Alfa | Phase 2 | Lysosomal Acid Lipase Deficiency |
| Bertilimumab | Phase 2 | Pemphigoid, Bullous |
| Sovaprevir | Phase 2 | Hepatitis C, Chronic |
| Danicopan | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| ALXN2350 | Phase 1/2 | BAG3 Mutation Associated Dilated Cardiomyopathy |
| AZD0120 | Phase 1/2 | Relapsed AL Amyloidosis |
| Elvucitabine | Phase 1/2 | HIV Infections |
| ALXN2230 | Phase 1 | |
| ALXN2050 | Phase 1 | |
| ALXN1720 SC | Phase 1 | Healthy |
| ALXN2050 MR Prototype Tablet | Phase 1 | Healthy Participants |
| Vemircopan | Phase 1 | Healthy Participants |
| Acoramidis | Phase 1 | Healthy |
| [14C]-Danicopan | Phase 1 | Healthy |
| ALXN2080 | Phase 1 | Healthy |
| ALXN1007 | Phase 1 | Healthy |
| ACH-0143102 | Phase 1 | Chronic Hepatitis C Infection |
| Danicopan Modified Release Prototype 1 | Phase 1 | Healthy |
| ALXN1210 | Phase 1 | Healthy |
| ALXN1820 SC | Phase 1 | Healthy |
| ACH-126, 443 (beta-L-Fd4C) | Not Applicable | Chronic Hepatitis B |
Latest
Follow Alexion on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.